Salt Lake City, UT, July 30, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the growing use of the Company’s Vector Smart™ NAM-W test by mosquito abatement districts to identify the presence of West Nile virus (WNV).
Press coverage from July 27 reported on mosquito abatement districts already using the Company’s NAM-W test in their pursuit of improving public health, and provided background on the scope and mission of those districts. Diseases like WNV are carried across the continent by migratory birds or other vectors, and are then transmitted to humans or livestock by mosquitoes. The presence of WNV has been reported in counties across the state of Utah this mosquito season; local press as far away as New York City has reported the same.
The article states:
"Usually, when sent to state labs, abatement districts learn whether their mosquitoes test positive for West Nile within one to two weeks. But Co-Diagnostics has developed a test, called NAM-W, that the company says uses technology in a faster, more affordable way, allowing districts to get results within a day.”
In addition to West Nile, the multiplex polymerase chain reaction (PCR) Vector Smart NAM-W also tests for the presence of St. Louis encephalitis and western equine encephalitis in mosquito populations. A Vector Smart NAM-E test is currently planned which would identify eastern equine encephalitis, a disease that kills roughly one-third of those infected and typically leaves survivors with “mild to severe brain damage” according to the CDC. Eastern equine encephalitis was recently detected in Orange County, FL. The Company’s product line will also soon be expanded to include a Vector Smart version of their CE-marked Logix Smart™ ZDC (Zika, dengue, and chikungunya) multiplex test, optimized for mosquito populations.
Co-Diagnostics CEO Dwight Egan commented, “The recent article highlights the public health benefits of our multiplex PCR solutions which allow for the detection of a variety of diseases, making them the most competitive tests in this market, and providing results within hours as opposed to a week or more. Mosquito control activities are more accurate, efficient, and effective the sooner disease-carrying mosquitoes are identified. Deliveries of our unique and high-performance Vector Smart mosquito tests to abatement districts and research institutions across the country are already underway, and our pipeline for additional vector control tests will continue to expand in response to the needs of this growing market.”
More information about the Company’s vector control solutions, pricing for the laboratory equipment packages, and tests currently available or in development can be found on the Company’s website at http://codiagnostics.com/products/vector-solutions/.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Company Contact:
Andrew Benson
Head of Investor Relations
+1 801-438-1036
investors@codiagnostics.com